The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

Completed

Phase 0 Results N/A

Summary of Purpose

Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2, a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will induce secondary peri-blood clot edema and...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 November 2015.

1 Mar 2011 28 Mar 2011 1 Sep 2013 1 Sep 2013 1 Dec 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Chun-Chung CC Chen, MD